Amylyx Pharmaceuticals In... (AMLX)
Amylyx Pharmaceuticals Statistics
Share Statistics
Amylyx Pharmaceuticals has 88.6M shares outstanding. The number of shares has increased by 30.29% in one year.
| Shares Outstanding | 88.6M |
| Shares Change (YoY) | 30.29% |
| Shares Change (QoQ) | 29.26% |
| Owned by Institutions (%) | 73.12% |
| Shares Floating | 63.86M |
| Failed to Deliver (FTD) Shares | 110 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 3.78M, so 4.26% of the outstanding shares have been sold short.
| Short Interest | 3.78M |
| Short % of Shares Out | 4.26% |
| Short % of Float | 4.58% |
| Short Ratio (days to cover) | 6.02 |
Valuation Ratios
The PE ratio is -0.85 and the forward PE ratio is -2.12. Amylyx Pharmaceuticals's PEG ratio is 0.
| PE Ratio | -0.85 |
| Forward PE | -2.12 |
| PS Ratio | 2.95 |
| Forward PS | 2.4 |
| PB Ratio | 1.56 |
| P/FCF Ratio | -1.53 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Amylyx Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.67, with a Debt / Equity ratio of 0.01.
| Current Ratio | 6.67 |
| Quick Ratio | 6.67 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.01 |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $710.33K |
| Profits Per Employee | $-2.45M |
| Employee Count | 123 |
| Asset Turnover | 0.45 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -393K |
| Effective Tax Rate | 0.13% |
Stock Price Statistics
The stock price has increased by 112.83% in the last 52 weeks. The beta is -0.53, so Amylyx Pharmaceuticals's price volatility has been lower than the market average.
| Beta | -0.53 |
| 52-Week Price Change | 112.83% |
| 50-Day Moving Average | 3.57 |
| 200-Day Moving Average | 3.52 |
| Relative Strength Index (RSI) | 59.36 |
| Average Volume (20 Days) | 824.98K |
Income Statement
In the last 12 months, Amylyx Pharmaceuticals had revenue of 87.37M and earned -301.74M in profits. Earnings per share was -4.43.
| Revenue | 87.37M |
| Gross Profit | 45.22M |
| Operating Income | -314.73M |
| Net Income | -301.74M |
| EBITDA | -290.98M |
| EBIT | -291.88M |
| Earnings Per Share (EPS) | -4.43 |
Balance Sheet
The company has 77.39M in cash and 1.98M in debt, giving a net cash position of 75.41M.
| Cash & Cash Equivalents | 77.39M |
| Total Debt | 1.98M |
| Net Cash | 75.41M |
| Retained Earnings | -606.69M |
| Total Assets | 193.63M |
| Working Capital | 161.03M |
Cash Flow
In the last 12 months, operating cash flow was -167.65M and capital expenditures -157K, giving a free cash flow of -167.8M.
| Operating Cash Flow | -167.65M |
| Capital Expenditures | -157K |
| Free Cash Flow | -167.8M |
| FCF Per Share | -2.46 |
Margins
Gross margin is 51.75%, with operating and profit margins of -360.22% and -345.36%.
| Gross Margin | 51.75% |
| Operating Margin | -360.22% |
| Pretax Margin | -345.81% |
| Profit Margin | -345.36% |
| EBITDA Margin | -333.03% |
| EBIT Margin | -360.22% |
| FCF Margin | -192.06% |
Dividends & Yields
AMLX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for AMLX is $7, which is 75.9% higher than the current price. The consensus rating is "Hold".
| Price Target | $7 |
| Price Target Difference | 75.9% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -0.11 |
| Piotroski F-Score | 3 |